Although EMPD lesions generally lack better predictors of tumor response with immune checkpoint inhibitors, such as high PD-L1/L2 expression and presence of MSI-H status, that does not mean that there would be poor anti-tumor effect from checkpoint inhibitors in all EMPD cases. The gene discussed is CD274; the disease is extramammary Paget disease.